AIM
AUPH icon

Acropolis Investment Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Acropolis Investment Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$318K Hold
19,657
– – 0.01% 234
2026
Q2 		$334K Hold
19,657
– – 0.01% 229
2026
Q1 		$291K Sell
19,657
-8,868
-31% -$130K 0.01% 236
2025
Q4 		$455K Hold
28,525
– – 0.02% 182
2025
Q3 		$242K Hold
28,525
– – 0.01% 235
2025
Q2 		$242K Buy
+28,525
New +$229K 0.01% 220

Other funds holding AUPH

JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Acropolis Investment Management's AUPH Position: Q3 2026 in Review

Acropolis Investment Management held its Aurinia Pharmaceuticals (AUPH) position steady in Q3 2026 at 19,657 shares worth $318K. The position accounts for 0.01% of the portfolio, ranked #234.

Acropolis Investment Management first reported a position in AUPH in Q2 2025 and has held it in 6 quarters since. The position peaked at $455K in Q4 2025. 7 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

  • Acropolis Investment Management held 19,657 shares of Aurinia Pharmaceuticals worth $318K as of Q3 2026.
  • Acropolis Investment Management left its Aurinia Pharmaceuticals share count unchanged in Q3 2026.
  • Aurinia Pharmaceuticals made up 0.01% of Acropolis Investment Management's portfolio in Q3 2026, its #234 holding.
  • Acropolis Investment Management first reported a position in Aurinia Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Acropolis Investment Management's Aurinia Pharmaceuticals position peaked at $455K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on Acropolis Investment Management's 13F filing for Q3 2026, filed 8 Oct 2026.